<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03905408</url>
  </required_header>
  <id_info>
    <org_study_id>PLUG-I</org_study_id>
    <nct_id>NCT03905408</nct_id>
  </id_info>
  <brief_title>Pleurodesis Using Hypertonic Glucose to Treat Post-operative Air Leaks</brief_title>
  <acronym>PLUG-I</acronym>
  <official_title>PLeurodesis Using Hypertonic Glucose Administration to Treat Post-operative Air Leaks Following Lung Resection Surgery (PLUG-I): Phase 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will define the most appropriate safe dose of D50 to heal air leaks in&#xD;
      patients that have undergone lung resection surgery&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will define the most appropriate safe dose of D50 to heal air leaks in&#xD;
      patients that have undergone lung resection surgery (Phase I study). Air leaks from unhealed&#xD;
      lung tissue are one of the most common complications after lung surgery including wedge&#xD;
      resection, segmentectomy and lobectomy. Air leaks can lead to a delay in chest tube removal,&#xD;
      prolonged pain, increased infections, prolonged hospital stay, and increased costs to the&#xD;
      health care system. Different agents have been used to heal air leaks by creating a&#xD;
      pleurodesis (adhesions to obliterate the pleural space between the visceral and parietal&#xD;
      pleura). The success with these agents has been variable and come with the cost of&#xD;
      complications that have restricted their use the post-operative period. There has been recent&#xD;
      interest in the use of 50% hypertonic glucose (D50) to create pleurodesis with encouraging&#xD;
      reports coming mostly from Asia. The investigators have performed a pilot study using 180 mL&#xD;
      of D50 instilled through the chest tube for the management of post lobectomy air leak with&#xD;
      very encouraging results. This preliminary study used strict inclusion criteria of only&#xD;
      lobectomy patients and excluded all patients with known diabetes or any postoperative&#xD;
      hyperglycemia. It is unknown if these patients would have benefitted from D50. Also, the&#xD;
      optimal dose of D50 was chosen empirically and never clearly defined by previous work. It has&#xD;
      been reported that high doses of D50 have been associated with acute lung injury. It is&#xD;
      therefore critical that the optimal safe dose is clarified.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 17, 2019</start_date>
  <completion_date type="Actual">February 1, 2021</completion_date>
  <primary_completion_date type="Actual">February 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Escalating dose:&#xD;
Arm 1: 50 mL dextrose 50% Arm 2: 100 mL dextrose 50% Arm 3: 150 mL dextrose 50% Arm 4:, 200 mL dextrose 50%</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of treatment related adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>occurrence of treatment related adverse events (Grade 3 and more as assessed to the CTCAE v4.0) at any given dose of D50</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Postoperative Air Leak</condition>
  <arm_group>
    <arm_group_label>50 mL Dextrose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mL of 50% dextrose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mL Dextrose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mL of 50% dextrose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150 mL Dextrose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mL of 50% dextrose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mL Dextrose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mL of 50% dextrose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50 mL of 50% Glucose</intervention_name>
    <description>1st dose</description>
    <arm_group_label>50 mL Dextrose</arm_group_label>
    <other_name>Dextrose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 mL of 50% Glucose</intervention_name>
    <description>2nd dose</description>
    <arm_group_label>100 mL Dextrose</arm_group_label>
    <other_name>Dextrose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>150 mL of 50% Glucose</intervention_name>
    <description>3rd dose</description>
    <arm_group_label>150 mL Dextrose</arm_group_label>
    <other_name>Dextrose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>200 mL of 50% Glucose</intervention_name>
    <description>4th dose</description>
    <arm_group_label>200 mL Dextrose</arm_group_label>
    <other_name>Dextrose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years old or older&#xD;
&#xD;
          2. Lung resection is a wedge, segmentectomy, lobectomy or bilobectomy&#xD;
&#xD;
          3. Procedure performed by video-assisted thoracic surgery (VATS) or by Thoracotomy&#xD;
&#xD;
          4. Presence of an air leak on the digital draining system on postoperative day 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Large air leak arbitrarily defined as more than 1000 mL/min&#xD;
&#xD;
          2. Allergy to local anesthetics&#xD;
&#xD;
          3. Hemodynamic instability&#xD;
&#xD;
          4. Untreated coronary artery disease&#xD;
&#xD;
          5. Need for respiratory support&#xD;
&#xD;
          6. Any other early post-operative complication&#xD;
&#xD;
          7. Immunity disorder&#xD;
&#xD;
          8. Large pleural fluid output empirically defined as more than 500 mL in the last 12&#xD;
             hours&#xD;
&#xD;
          9. Inability to give consent&#xD;
&#xD;
         10. Fasting glucose ≥ 14 mmol/L the morning of the intervention (arbitrarily chosen&#xD;
             cut-off in which patients' diabetes is considered very poorly controlled)&#xD;
&#xD;
         11. Endocrinology service not available to co-manage patients with either diabetes, or a&#xD;
             fasting blood glucose ≥ 7 mmol/L, or HbA1c &gt; 6.5%&#xD;
&#xD;
         12. Postoperative evidence of an active thoracic (lung or pleura) infection with systemic&#xD;
             inflammatory response syndrome (2 or more of temperature &gt; 38, heart rate &gt; 90,&#xD;
             respiratory rate &gt; 20, white blood cell count &gt; 12)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 26, 2019</study_first_submitted>
  <study_first_submitted_qc>April 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2019</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Richard Malthaner</investigator_full_name>
    <investigator_title>MD, Chair/Chief Thoracic Surgery</investigator_title>
  </responsible_party>
  <keyword>glucose</keyword>
  <keyword>lung surgery</keyword>
  <keyword>air leak</keyword>
  <keyword>postoperative</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

